Non-small cell lung cancer: an update on emerging EGFR-targeted therapies

Expert Opin Emerg Drugs. 2024 Apr 4. doi: 10.1080/14728214.2024.2331139. Online ahead of print.ABSTRACTINTRODUCTION: Current research in EGFR-mutated NSCLC focuses on the management of drug resistance and uncommon mutations, as well as on the opportunity to extend targeted therapies' field of action to earlier stages of disease.AREAS COVERED: We conducted a review analyzing literature from the PubMed database with the aim to describe the current state of art in the management of EGFR-mutated NSCLC, but also to explore new strategies under investigation. To this purpose, we collected recruiting phase II-III trials registered on Clinicaltrials.gov, conducted in EGFR-mutated NSCLC both in early and advanced stage.EXPERT OPINION: With this review we want to provide an exhaustive overview of current and new potential treatments in EGFR-mutated NSCLC, with emphasis on the most promising newly investigated strategies, such as association therapies in the first-line setting involving EGFR-TKIs and chemotherapy (FLAURA2) or drugs targeting different driver pathways (MARIPOSA). We also aimed at unearthing challenges to achieve in this field, specifically the need to fully exploit already available compounds while developing new ones, the management of new emerging toxicities and the necessity to improve our biological understanding of the disease to design trials with a solid scientific rationale and to allow treatment personalization such in case of uncommon mutations.PMID:38572595 | ...
Source: Expert Opinion on Emerging Drugs - Category: Drugs & Pharmacology Authors: Source Type: research